Registered title, quoted from ClinicalTrials.gov
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Shenzhen University General Hospital; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07508605, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) classification;
Inclusion criterion 2
CD20 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry;
Inclusion criterion 5
New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <50% on echocardiography;
Inclusion criterion 16
No antibody-based therapy within 2 weeks prior to cell therapy. Exclusion Criteria
Inclusion criterion 12
ECOG performance status of 0-2;
Inclusion criterion 3
Abnormal complete blood count meeting any of the following: WBC ≤1 × 10⁹/L, ANC ≤0.5 × 10⁹/L, ALC ≤0.5 × 10⁹/L, or PLT ≤25 × 10⁹/L;
Inclusion criterion 14
Laboratory abnormalities including, but not limited to, any of the following: total serum bilirubin ≥1.5 mg/dL; ALT or AST >2.5 times the upper limit of normal; serum creatinine ≥2.0 mg/dL;
Inclusion criterion 15
At least one measurable and evaluable lesion according to RECIST 1.1;
Inclusion criterion 10
currently pregnant or breastfeeding;
Inclusion criterion 29
planning to become pregnant during the study period; or
Inclusion criterion 30
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07508605, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria
Subjects must meet all of the following criteria to be enrolled:
- Aged 18 to 75 years, regardless of sex;
- Histologically confirmed relapsed/refractory B-cell lymphoma according to the 2020 World Health Organization (WHO) classification;
- ECOG performance status of 0-2;
- Expected survival of at least 3 months;
- CD20 expression on tumor cells confirmed by flow cytometry and/or immunohistochemistry;
- Patients who are resistant/refractory to CD19 CAR-T cell therapy or have low CD19 expression;
- No severe cardiac, pulmonary, hepatic, or renal disease;
- Able to understand and willing to sign the informed consent form for this study;
- No contraindications to peripheral blood mononuclear cell collection/apheresis;
- At least one measurable and evaluable lesion according to RECIST 1.1;
- Must have previously received standard first-line and second-line therapy;
- No antibody-based therapy within 2 weeks prior to cell therapy. Exclusion Criteria
Subjects meeting any of the following criteria will be excluded:
- History of allergy to any component of the cell product;
- Abnormal complete blood count meeting any of the following: WBC ≤1 × 10⁹/L, ANC ≤0.5 × 10⁹/L, ALC ≤0.5 × 10⁹/L, or PLT ≤25 × 10⁹/L;
- Laboratory abnormalities including, but not limited to, any of the following: total serum bilirubin ≥1.5 mg/dL; ALT or AST >2.5 times the upper limit of normal; serum creatinine ≥2.0 mg/dL;
- New York Heart Association (NYHA) Class III or IV heart failure, or left ventricular ejection fraction (LVEF) <50% on echocardiography;
- Abnormal pulmonary function, with oxygen saturation <92% on room air;
- History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant severe cardiac disease within 12 months prior to enrollment;
- Grade 3 hypertension with poor blood pressure control despite medication;
- History of craniocerebral trauma, disturbance of consciousness, epilepsy, severe cerebral ischemia, or cerebral hemorrhagic disease;
- Presence of autoimmune disease, immunodeficiency, or other conditions requiring immunosuppressive therapy;
- Presence of uncontrolled active infection;
- Prior treatment with any CAR-T cell product or other genetically modified T-cell therapy;
- Receipt of a live vaccine within 4 weeks prior to enrollment;
- Positive for HIV, HBV, HCV, or TPPA/RPR, or HBV carrier status;
- History of alcohol abuse, drug abuse, or psychiatric illness;
- Participation in any other clinical study within 3 months prior to enrollment in this study;
- Female subjects meeting any of the following conditions:
- currently pregnant or breastfeeding;
- planning to become pregnant during the study period; or
- of childbearing potential and unwilling or unable to use effective contraception;
- Any other condition that, in the investigator's judgment, makes the subject unsuitable for participation in this study.
Quoted from ClinicalTrials.gov, NCT07508605, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07508605, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.